Clinical biochemistry & Rheumatology & Endocrinology
Osteocalcin (bone remodeling marker)
Osteocalcin—also known as BGP (Bone Gla Protein, a bone protein rich in γ-carboxyglutamic acid residues)—is the most abundant non-collagenous protein in the bone matrix, synthesized and secreted exclusively by mature osteoblasts and, to a lesser extent, by hypertrophic chondrocytes. Composed of 49 amino acids, it contains three γ-carboxyglutamic acid (Gla) residues whose carboxylation depends on vitamin K, which gives it a high affinity for calcium ions and hydroxyapatite in the mineralized matrix—its primary role being to participate in bone mineralization and the regulation of hydroxyapatite crystal size. During bone remodeling, a fraction of the osteocalcin produced by osteoblasts is released into the bloodstream without being incorporated into the matrix, allowing for its serum measurement as a biomarker of osteoblastic activity and bone formation. Its serum concentration thus directly reflects the rate of bone formation: it rises in all situations involving activated bone remodeling (adolescence, healing fractures, menopause, hyperparathyroidism, Paget’s disease) and decreases when bone formation is suppressed (corticosteroid therapy, severe hypothyroidism, hypoparathyroidism). In contemporary clinical practice, however, osteocalcin is gradually being supplanted as the preferred marker of bone formation by P1NP (N-terminal propeptide of type I procollagen), which is recommended by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) as the reference marker for bone formation in the monitoring of osteoporosis, due to its greater preanalytical stability and lower biological variability. Osteocalcin nevertheless remains of interest in research and in certain specific clinical contexts, and several recent studies have attributed unexpected extra-osseous hormonal functions to it—notably an effect on the regulation of blood glucose, energy metabolism, male fertility, and cognition—which make it a biomarker with potential far beyond bone metabolism alone.
Biology and pre-analytics
- Synthesis and secretion: synthesis exclusively by mature osteoblasts + carboxylation of Gla residues is vitamin K-dependent → vitamin K deficiency produces undercarboxylated osteocalcin (ucOC) which is released into the circulation without bone incorporation + circulating fraction: intact OC (whole molecule) + N-terminal mid fragments (main fragments detected by immunoassays) + short serum half-life: 20-30 minutes for intact osteocalcin + accumulation in renal tubules → renal failure increases serum osteocalcin concentrations independently of bone remodeling
- Circadian and seasonal variations marked circadian rhythm - nocturnal peak (around 4-6 a.m.) + mid-afternoon nadir → daily variation of 15-30 % → standardized sampling recommended: morning on an empty stomach + between 8 and 10 a.m. + after at least 30 minutes' rest + same time at each check + seasonal variation: higher values in winter (vitamin D deficiency) + lower in summer
- Pre-analytical stability — Osteocalcin's weak point: osteocalcin is highly sensitive to proteolytic degradation + unstable at room temperature (loses 50 % of its activity in 24 hours at 4°C) + the sample must be centrifuged quickly + the serum separated + frozen at -20°C or -80°C if the assay is delayed + transported on ice → it is precisely this preanalytical instability that limits its practical use compared with P1NP (stable for several days at 4°C) and CTX (stable at -20°C)
- Assay methods immunoassays (ELISA + RIA + ECLIA + CLIA) using antibodies directed against different epitopes of the molecule → results are not interchangeable between laboratories using different kits → important to always follow the same patient with the same method in the same laboratory
Reference values
| Population | Usual serum osteocalcin values | Remarks |
|---|---|---|
| Premenopausal woman (18–50 years old) | 11 to 43 µg/L (ng/mL) | Most stable values of adult female life + menstrual cycle slightly influences values (slight elevation in follicular phase) |
| Postmenopausal woman (50–65 years old) | 15 to 46 µg/L | Often significant increase in the first 5 years post-menopause (estrogen deficiency-induced bone remodeling activation) + gradually decreases after 65-70 years |
| Elderly woman (> 70 years old) | 12 to 55 µg/L | Wider variability + delicate interpretation due to frequent relative renal insufficiency and multiple comorbidities |
| Adult male (25–70 years old) | 14 to 42 µg/L | Slightly higher values than in premenopausal women + progressive decrease with age after 50-60 years |
| Children and teenagers | 50 to 150 µg/L or more depending on age | Very high values during bone growth (up to 5 to 10 times adult values at peak pubertal growth) → always interpret according to specific age-related pediatric standards |
| Note on the unit | Results can be expressed in µg/L = ng/mL = nmol/L (conversion factor: 1 µg/L ≈ 0.167 nmol/L for human osteocalcin MW 5,800 Da) + check the unit reported by the laboratory before interpretation | |
ℹ️
Osteocalcin reference values vary depending on the assay method, laboratory, and reference population used. The reference intervals published here are indicative. Always interpret the result using the reference values from the laboratory that performed the assay, and ensure that successive tests for the same patient are performed in the same laboratory using the same method to allow for valid comparison over time.
Causes of elevated osteocalcin
| Clinical situation | Mechanism | Context and degree of elevation |
|---|---|---|
| Menopause and estrogen deficiency | The drop in estrogen removes their inhibition on osteoclasts → activation of bone remodeling → coupled increase in resorption AND formation (formation markers rise in response to osteoclast activation) → increased osteocalcin in the first 5-10 years post-menopause | Moderate to significant elevation (sometimes doubling premenopausal values) + predictive signal of accelerated bone loss + very high osteocalcin in early postmenopause is an independent fracture risk factor. |
| Primary hyperparathyroidism | Excess PTH → direct stimulation of bone formation and resorption → elevation of all bone remodeling markers, including osteocalcin | Often moderate elevation in asymptomatic forms + significant in forms with clinical bone involvement (osteitis fibrosa cystica) + to be corrected with surgical treatment (parathyroidectomy) |
| Bone Paget's disease | Locally disordered and accelerated bone remodeling → massive osteoblastic hyperactivity → very significant elevation of bone formation and resorption markers | Major elevation (often 5 to 10 times normal) + correlates with disease extent + bone alkaline phosphatase also very high + very high CTX (coupled resorption) |
| Fracture healing | Intense osteoblast activation during bone callus formation → transient increase in osteocalcin in the weeks following a fracture | Temporary elevation of 6 to 12 weeks + returns to normal once consolidation is complete + may interfere with interpretation if dosage is performed shortly after a fracture |
| Hyperthyroidism | Thyroid hormones directly stimulate osteoblasts and osteoclasts → activation of remodeling + accelerated bone loss + elevation of markers of formation and resorption | Elevation proportional to the severity of hyperthyroidism + normalization after treatment of hyperthyroidism (often within a few months) |
| Childhood and adolescence | Active bone growth → physiological osteoblastic hyperactivity → normal very high values throughout the growth period | Normal values for age but very high compared to adult norms + peak at the time of pubertal acceleration + always use adapted pediatric norms |
Causes of low osteocalcin
- Systemic corticosteroid therapy: main drug responsible for low osteocalcin + glucocorticoids directly inhibit osteocalcin gene transcription in osteoblasts → rapid reduction in osteocalcin synthesis from the first weeks of treatment → low osteocalcin on corticosteroids reflects inhibition of bone formation responsible for cortisone-induced osteoporosis + suppression is dose-dependent and reversible + interest in osteocalcin monitoring in cortisone-induced osteoporosisdependent and reversible on discontinuation of treatment + osteocalcin is useful for monitoring cortisone-induced osteoporosis
- Bisphosphonates and denosumab: bisphosphonates (alendronate + risedronate + zoledronic acid) inhibit osteoclastic resorption → bone coupling → secondary reduction in bone formation → decrease in osteocalcin (and P1NP) from 40 to 70 % after 3 to 6 months of treatment → suppression of formation markers under bisphosphonates confirms efficacy of anti-resorptive therapy
- Hypoparathyroidism: PTH deficiency → reduced bone remodeling → decreased bone formation and resorption → low osteocalcin + low blood calcium + high blood phosphorus (typical workup)
- Severe hypothyroidism overall slowdown in metabolism, including bone remodelling → decrease in formation and resorption markers + normalization after hormone replacement therapy
- Type 2 Diabetes: recent data suggest that under-carboxylated osteocalcin (ucOC) is lower in patients with type 2 diabetes + obesity - this deficit may contribute to insulin resistance (see hormonal functions of osteocalcin) + total osteocalcin is also lowered in type 2 diabetes probably through high insulin levels inhibiting osteocalcin secretion
Osteocalcin and Extraosseous Hormonal Functions
- Blood glucose and energy metabolism regulation: work by Gerard Karsenty (Columbia University - Cell 2007) → under-carboxylated osteocalcin (ucOC) acts as an endocrine hormone + stimulates insulin secretion by pancreatic beta cells + improves insulin sensitivity in muscle and adipose tissue + increases energy expenditure + in mice, osteocalcin gene invalidation induces type 2 diabetes and obesity + clinical relevance in humans still under evaluation, but several epidemiological studies associate low osteocalcin with an increased risk of type 2 diabetes and metabolic syndrome
- Male fertility: osteocalcin stimulates testosterone production by testicular Leydig cells via a specific receptor (GPRC6A) + promotes spermatogenesis + in male mice with inactivated osteocalcin receptors → hypogonadism and infertility + potential link with male hypogonadism associated with osteoporosis in aging men
- Cognition and memory: osteocalcin crosses the blood-brain barrier + stimulates synthesis of cerebral monoamines (dopamine + serotonin + noradrenaline) + improves memory performance in mouse models + plasma osteocalcin declines with age + may contribute to age-related cognitive decline + human studies underway
- Current clinical note : these hormonal functions are well-established in mice, but clinical transposition to humans has yet to be formally confirmed by clinical trials + osteocalcin is not yet used as a biomarker or therapeutic target for these indications in standard clinical practice
Osteocalcin versus P1NP and CTX — which bone marker to use?
- P1NP (N-terminal propeptide of procollagen type I) — a preferred marker of bone formation: recommended by IOF + IFCC + Osteoporosis Canada as a reference marker of bone formation in the monitoring of osteoporosis + better pre-analytical stability than osteocalcin + lower biological variability + assay in serum or plasma + stable for 24 h at room temperature + superior to osteocalcin for monitoring anti-osteoporosis treatment + recommended as first-line treatment
- CTX (C-terminal cross-linking telopeptide of type I collagen) — a preferential marker of bone resorption: recommended by the IOF + IFCC as a reference marker of bone resorption + morning fasting serum assay (very marked circadian variation - 30-40 % depending on the time of day) + reflection of osteoclastic activity + most widely used in practice for monitoring bisphosphonates and denosumab
- Osteocalcin - When to Prescribe It Still? global assessment of bone remodelling as a complement to P1NP and CTX + search for severe suppression of bone remodelling on bisphosphonates (very low osteocalcin = excessive suppression of remodelling → theoretical risk of atypical fracture) + research context (endocrine functions) + situations where P1NP is not available locally + assessment of cortisone-induced osteoporosis
Medical consultation recommended
A very high or very low osteocalcin result discovered incidentally must be interpreted in a clinical context by a doctor—it can never be interpreted in isolation. Very high osteocalcin can indicate undiagnosed hyperparathyroidism, Paget's disease, hyperthyroidism, or premature menopause—conditions that warrant a complete workup and treatment. Low osteocalcin in a patient on corticosteroids without bone supplementation or densitometric assessment should lead to prescribing a DXA and considering preventive anti-osteoporotic treatment.
For the assessment of bone metabolism, including osteocalcin, P1NP, CTX, calcium, vitamin D, and DXA, in the context of osteoporosis monitoring or suspected bone disease, Clinique Omicron offers medical consultations at its service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's nurse practitioners (NPs) prescribe and interpret bone remodeling markers (osteocalcin + P1NP + CTX) as part of osteoporosis assessment, monitoring of anti-osteoporosis treatment, surveillance of corticosteroid-induced osteoporosis, and investigation of hypercalcemia or metabolic bone disease. Appointments are available at several service locations in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for medical advice from a physician, rheumatologist, or endocrinologist. The interpretation of bone remodeling markers must always be integrated within the overall clinical context (age + sex + current treatments + comorbidities) and cannot be done in isolation.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.